LIFEVANTAGE CORP Form DEFC14A: Definitive proxy statement in a contested solicitation
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-09-25: Form DEFC14A; Description Definitive proxy statement in a contested solicitation; Document defc14a09076057_09252023.htm.
- 2023-09-22: Form DEFC14A; Description DEFC14A; Document lfvnproxystatementfy2024-f.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2023-09-25 | DEFC14A | Definitive proxy statement in a contested solicitation | defc14a09076057_09252023.htm | |
| 2023-09-22 | DEFC14A | DEFC14A | lfvnproxystatementfy2024-f.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |